Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 Combined With Chemotherapy in Advanced Pancreatic Cancer
NCT07232875Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Nov 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-4642 in pancreatic adenocarcinoma (PDAC), sponsored by Hengrui. Started Nov 2025; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07232875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232875.